至2016年的免疫調節劑市場展望

至2016年的免疫調節劑市場展望 是由出版商Business Insights在2011年08月所出版的。 這份英文市場調查報告書包含Pages: 159 價格從美金3835起跳。

簡介

適應於類風濕性關節炎和乾癬、發炎性腸道疾病治療的TNF抑制劑佔有廣大的市佔率，Remicade、Humira、Enbrel佔了2010年市場的40.1％。此外，Novartis針對多發性硬化症的經口藥物Gilenya也擴大市佔率，預期2016年將達到23億美元的業績。

本報告，全面分析全球的免疫調節劑市場，彙整疾病的概要與流行病學、已上市的主力產品、研發產品線、至2015年的業績預測等，由下列摘要形式闡述。

報告摘要

簡介

醫療裝置部門的合併・收購

• 摘要
• 簡介
  • 免疫系統結構
  • 獲得免疫的構造
  • 補充系統
• 動向
  • 類風濕性關節炎的未滿足需求
  • 克隆氏症的的未滿足需求
  • 多發性硬化症的未滿足需求
  • 針對單株抗體生物仿製藥的EU指導方針
  • 移植相關的倫理問題
• 市場規模
  • 全球市場規模
  • 地區別市場區塊

多發性硬化症

• 摘要
• 簡介
• 疾病概要
  • 定義
  • 臨床症狀
  • 種類
  • 病因
  • 病態生理學
  • 診斷
  • 治療
  • 經濟負擔
  • 流行病學
  • 預測流行病學
• 現在已上市的治療方法
• 主要企業
  • Biogen IDEC
  • Bayer
  • Teva
  • Merck Serono
  • Novartis
• 主要的產品線產品
• 業績預測

類風濕性關節炎、乾癬、發炎性腸道疾病

• 摘要
• 簡介
• 類風濕性關節炎
• 發炎性腸道疾病
• 乾癬
• 現在已上市的治療藥物
• 非抗TNF生物製劑
• 主要企業
  • Pfizer
  • Abbott
  • Johson & Johnson
• 主要的產品線產品
• 業績預測

全身紅斑性狼瘡

• 摘要
• 簡介
• 疾病概要
• 現在已上市的治療方法
• 主要的產品線產品

器官移植

• 摘要
• 簡介
• 疾病概要
• 排斥的免疫生物學
• 排斥的機制
• 排斥的階段
• 急性排斥反應事件
• 流行病學
• 現在已上市的治療方法
• 主要企業
• 主要的產品線產品

附錄

圖表

目錄

Abstract

Introduction

The report provides comprehensive coverage of the global immunomodulators market, incorporating disease overviews, and epidemiological analyses. This report captures and assesses leading marketed products, R&D pipelines, sales forecast and key market players. It also highlights key trends that will influence sales through 2016.

Features and benefits

• Assess the patient potential and treatment trends of the major immune related diseases globally.
• Analyse the dynamics of the immunomodulators market and understand the impact of key R&D events, market trends, and issues.
• Gain up-to-date competitive intelligence and understand the major issues affecting key pharmaceutical marketers.
• Identify the leading pipeline products in the forecast sales to 2016.
• Develop strategies for success in the future CNS market.

Highlights

TNF inhibitors indicated for the treatment of rheumatoid arthritis, psoriasis and inflammatory bowel disease formed the largest share of the market, with the top three products: Remicade, Humira and Enbrel accounting for 40.1% of the market in 2010.

Novartis' orally formulated Gilenya for multiple sclerosis will gain extensive market share reaching sales of $2.3bn by 2016. Copaxone and Avonex sales will decline strongly to 2016.

GSK and Human Genome Sciences' Benlysta was the first product to be approved for the treatment of systemic lupus erythematous in the past 30 years, a key step in the disease treatment. Benlysta will reach sales of $401m in 2016.

Your key questions answered

• What are the current growth drivers in the global immunomodulator market?
• What are the new therapeutic approaches in the immunomodulators market and which of these offer significant potential in the future?
• What is the forecast commercial potential of the most promising compounds in clinical development?
• Who are the leading players in each indication in the immunomodulators market, and what are their strategies?
• How will the launch of late stage pipeline products and patent expires impact the market to 2016?

Table of Contents

About the author

• Disclaimer

EXECUTIVE SUMMARY

• Introduction
• Multiple sclerosis
• Rheumatoid arthritis, psoriasis and inflammatory bowel disease
• Systemic lupus erythematosus
• Organ transplantation

Introduction

• Summary

• Introduction
  • Components of the immune system
  • Components of acquired immunity
  • The complement system

• Trends
  • Unmet need in rheumatoid arthritis
  • Unmet needs in Crohn' s disease
  • Unmet need in multiple sclerosis
  • EU guidelines for monoclonal antibodies biosimilars
  • Ethical concerns over transplantation

• Market size
  • Global market size
  • Geographic segmentation

Multiple sclerosis

• Summary
• Introduction

• Disease overview
  • Definition
  • Clinical manifestation of multiple sclerosis
  • Types of multiple sclerosis
  • Etiology
  • Pathophysiology
  • Diagnosis
  • Treatment
  • Economic burden of disease
  • Epidemiology
  • Forecast epidemiology

• Current marketed therapies
  • Copaxone
  • Avonex
  • Rebif
  • Betaseron
  • Tysabri

• Key players
  • Biogen IDEC
  • Bayer
  • Teva
  • Merck Serono
  • Novartis

• Key pipeline products
  • BG-12/Panaclar - Biogen IDEC
  • Alemtuzumab - Genzyme
  • Teriflunomide - Sanofi
  • Laquinimod - Teva
  • Daclizumab

• Sales forecast

Rheumatoid arthritis, psoriasis and inflammatory bowel disease

• Summary
• Introduction

• Rheumatoid arthritis
  • Pathophysiology
  • Diagnosis
  • Treatment
  • Epidemiology
  • Forecast epidemiology

• Inflammatory bowel disease
  • Pathophysiology
  • Etiology
  • Diagnosis
  • Epidemiology
  • Forecast epidemiology

• Psoriasis
  • Overview
  • Pathogenesis
  • Symptoms
  • Treatment
  • Assessment of the response to biologicals
  • Epidemiology
  • Forecast epidemiology

• Current marketed therapies
  • Remicade
  • Simponi
  • Enbrel
  • Humira
  • Cimzia

• Non-anti-TNF biologics for rheumatoid arthritis
  • Rituxan/Mabthera
  • Orencia
  • Actemra

• Key players
  • Pfizer
  • Abbott
  • Johnson & Johnson

• Key pipeline products
  • Fostamatinib disodium - AstraZeneca
  • Tofacitinib - Pfizer

• Sales forecast

Systemic lupus erythematosus

• Summary
• Introduction

• Disease overview
  • Pathophysiology
  • Symptoms
  • Diagnosis
  • Treatment
  • Epidemiology
  • Forecast epidemiology

• Current marketed therapies
  • Benlysta
  • NSAIDs
  • Antimalarials
  • Glucocorticoids
  • Cytotoxic/immunosuppressive agents

• Key pipeline products
  • Lupuzor - Cephalon
  • Epratuzumab - UCB

• Sales forecast

Organ transplantation

• Summary
• Introduction
• Disease overview

• Immunobiology of rejection
  • Genetic factors

• Mechanisms of rejection
  • Apoptosis

• Stages of rejection
• Episode of acute rejection

• Epidemiology
  • Forecast number of transplants

• Current marketed therapies
  • Cellcept
  • Prograf

• Key players
  • Roche

• Key pipeline products
  • Nulojix - BMS
  • Voclosporin - Isotechnika

• Sales forecast

Appendix

• Scope

• Methodology
  • Market size methodology
  • Epidemiology
  • Market forecast

• Abbreviations
• Bibliography/references

TABLES

• Table: Total sales ($m) of the immunomodulators, 2010
• Table: Leading products in US immunomodulators market ($m), 2010
• Table: Leading products in the 5EU immunomodulators market ($m), 2010
• Table: Leading products in Japan immunomodulators market ($m), 2010
• Table: Poser criteria for diagnosis of multiple sclerosis
• Table: Revised McDonald criteria for diagnosis of multiple sclerosis
• Table: Annual per patient cost of multiple sclerosis ($)
• Table: Prevalence of multiple sclerosis by country
• Table: Forecast epidemiology of multiple sclerosis to 2016
• Table: Snapshot of the marketed products
• Table: Sales of leading multiple sclerosis products ($m), 2010
• Table: Forecast sales of marketed and pipeline products, 2010 - 16
• Table: Treatments for rheumatoid arthritis
• Table: Prevalence of rheumatoid arthritis, 2010
• Table: Forecast prevalence of rheumatoid arthritis, 2010 - 16
• Table: Differences between Crohn' s disease and ulcerative colitis
• Table: Diagnosis of IBD
• Table: Prevalence of Crohn' s disease
• Table: Prevalence of ulcerative colitis
• Table: Forecast prevalence of Crohn' s disease, 2010 - 16
• Table: Forecast prevalence of ulcerative colitis, 2010 - 16
• Table: Prevalence of psoriasis
• Table: Forecast prevalence of psoriasis, 2010 - 16
• Table: Snapshot of marketed products
• Table: Sales of the leading anti-TNF products, ($m) 2010
• Table: Sales of non-anti-TNF products ($m), 2010
• Table: Forecast sales of marketed and pipeline RA, IBD and psoriasis products ($m), 2010 - 16
• Table: Prevalence of Systemic lupus erythematosus
• Table: Forecast prevalence of SLE, 2010 - 16
• Table: Forecast sales ($m) of pipeline SLE products, 2010 - 16
• Table: Top ten countries by organ transplant numbers, 2009
• Table: Top ten countries by heart transplant numbers, 2009
• Table: Top ten countries by kidney transplant numbers, 2009
• Table: Top ten countries by liver transplant numbers, 2009
• Table: Forecast number of transplants, 2010 - 20
• Table: Forecast prevalence of functioning graft, 2010 - 20
• Table: Sales of leading products for organ transplant ($m), 2010
• Table: Forecast sales of marketed and pipeline transplant products, ($m), 2010 - 16

FIGURES

• Figure: Process of immune cell differentiation
• Figure: Immunomodulators market segmentation by region ($bn), 2010
• Figure: Demyelination of neuron
• Figure: Parts of the body affected by multiple sclerosis
• Figure: Disability progress rate in types of multiple sclerosis
• Figure: MRI scan report of a multiple sclerosis patient
• Figure: Demyelination mechanism
• Figure: MRI progress of multiple sclerosis
• Figure: Different analysis criteria used globally
• Figure: Causes of economic burden in multiple sclerosis
• Figure: Prevalence density of multiple sclerosis
• Figure: CHOICE trial description
• Figure: Rheumatoid arthritic bone
• Figure: Difference between a normal an arthritic joint
• Figure: Mechanism of action of TNF
• Figure: Products dosage based on indication
• Figure: Global transplants by organ, 2009

相關商品